The company said it was committed to expanding the range of goods and services it offers, which will improve the calibre of its earnings and the value to shareholders.
The Denosumab Biosimilars medications will be produced, registered, and marketed in Pakistan, according to a statement released on Wednesday by the pharmaceutical company The Searle Company Limited.
The company announced in a notice to Pakistan Stock Exchange (PSX) that it has a License Agreement in place with Mabwell Pharmaceuticals, China, to produce, register, and market Denosumab Biosimilars medicines in Pakistan.
Pakistan Stock Exchange surpasses 45,000 for the first time in 52 weeks to become the best stock market in the world. The partnership will provide Pakistani patients with high-quality, reasonably priced biological medicines, according to the statement.
The company said it was committed to expanding the range of goods and services it offers, which will improve the calibre of its earnings and the value to shareholders.
The primary business of the Searle Company is the production of pharmaceuticals and other consumer goods. The parent company, International Brands (Private) Limited, owns 56.32 percent of the shares in the company.
QL1206 (Qilu Pharmaceutical Co., Ltd., Jinan, China) is the first biosimilar of denosumab, and has the same chemical structure as denosumab.
Denosumab biosimilars are medications that are similar to the original biologic drug denosumab. Denosumab is a monoclonal antibody used in the treatment of osteoporosis, bone metastases, and other bone-related conditions.
Biosimilars are highly similar versions of an approved biologic drug, with comparable efficacy, safety, and quality. They are developed to be more affordable alternatives to the original biologic, providing increased access to treatment options for patients.
Denosumab biosimilars undergo rigorous testing and demonstration of similarity to the reference product to ensure their effectiveness and safety.
The SEARLE Company Ltd (TSCL) was incorporated in Pakistan as a Private Limited Company on October 5, 1965 as a subsidiary of G.D. Searle & Co., U.S.A. Today, Searle is one of the leading pharmaceutical companies in Pakistan having two state-of-the art manufacturing facilities in Lahore, and Karachi, Pakistan.